---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-237150"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:36:24.091071+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M

## Summary
- First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.
- Preclinical data at UEGW shows comparable potency to risankizumab with >3x half-life extension in NHPs (~30 days).
- Licensed IL-23 antibodies from Paragon for up to $22M in development/regulatory milestones plus low single-digit royalties.
- Portfolio includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.
- Combination data shows synergy of anti-IL-23 with anti-TL1A or anti-α4β7 in reducing IL-17 and inflammation in models.

## SEC filing metadata
- accession: 0001193125-24-237150
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312524237150/0001193125-24-237150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312524237150/d858952d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-237150
- JSON: https://secwatch.observer/filing/0001193125-24-237150.json
- Plain text: https://secwatch.observer/filing/0001193125-24-237150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.